- Home
- MFM vs FENC Comparison
MFM vs FENC Comparison
Compare MFM & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFM
- FENC
- Stock Information
- Founded
- MFM 1986
- FENC 1996
- Country
- MFM United States
- FENC United States
- Employees
- MFM N/A
- FENC N/A
- Industry
- MFM Finance Companies
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MFM Finance
- FENC Health Care
- Exchange
- MFM Nasdaq
- FENC Nasdaq
- Market Cap
- MFM 212.1M
- FENC 222.9M
- IPO Year
- MFM N/A
- FENC 2001
- Fundamental
- Price
- MFM $5.10
- FENC $8.41
- Analyst Decision
- MFM
- FENC Strong Buy
- Analyst Count
- MFM 0
- FENC 2
- Target Price
- MFM N/A
- FENC $13.00
- AVG Volume (30 Days)
- MFM 108.1K
- FENC 56.9K
- Earning Date
- MFM 01-01-0001
- FENC 08-12-2025
- Dividend Yield
- MFM 4.08%
- FENC N/A
- EPS Growth
- MFM N/A
- FENC N/A
- EPS
- MFM 0.03
- FENC N/A
- Revenue
- MFM N/A
- FENC $30,912,000.00
- Revenue This Year
- MFM N/A
- FENC $0.85
- Revenue Next Year
- MFM N/A
- FENC $55.16
- P/E Ratio
- MFM $176.67
- FENC N/A
- Revenue Growth
- MFM N/A
- FENC N/A
- 52 Week Low
- MFM $4.37
- FENC $3.96
- 52 Week High
- MFM $5.48
- FENC $9.30
- Technical
- Relative Strength Index (RSI)
- MFM 49.49
- FENC 48.09
- Support Level
- MFM $5.14
- FENC $8.41
- Resistance Level
- MFM $5.11
- FENC $8.94
- Average True Range (ATR)
- MFM 0.05
- FENC 0.36
- MACD
- MFM 0.00
- FENC -0.06
- Stochastic Oscillator
- MFM 50.00
- FENC 12.75
About MFM MFS Municipal Income Trust
MFS Municipal Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in municipal bonds.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.